Cambridge Research Biomedicals Extends Life Tech License | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Peptide and antibody maker Cambridge Research Biochemicals has extended a license agreement with Life Technologies that enables it to use the company's Molecular Probes line of dyes, CRB said today.

The extension of the agreement, originally formed in 2007, extends CRB's license to offer dye-labeled primary antibodies as well as peptides, the Billingham, UK-based firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.